Search research articles
Contact Us
Filters
Showing results (251-260 of 260) with videos related to
Page
of 26
Sort By:
You have reached the last page of results.
This site can display upto 260 results.
European Journal of Cancer (Oxford, England : 1990)
|
October 4, 2024
Olaparib as maintenance therapy in non resectable pancreatic adenocarcinoma associated with homologous recombination deficiency profile: A French retrospective multicentric AGEO real-world study
Jeannie M'Baloula, David Tougeron, Alice Boilève, et al.
Biology of the Cell
|
November 9, 2024
CRCI<sup>2</sup>NA inaugural symposium: A meeting on tumor and immune ecosystems
Vincent J Guen, Gwennan André-Grégoire, Céline Beauvillain, et al.
ESMO Real World Data and Digital Oncology
|
February 6, 2026
ESMO Guidance for Reporting Oncology real-World evidence (GROW)
L Castelo-Branco, A Pellat, D Martins-Branco, et al.
Cell Reports. Medicine
|
February 19, 2026
Targeting BCMA in multiple myeloma with a trifunctional NK cell engager
Alexandre Tang, Laurent Gauthier, Elisa Zaghi, et al.
Nature Communications
|
March 6, 2024
Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma
C Grandclément, C Estoppey, E Dheilly, et al.
Blood
|
May 16, 2023
Preclinical characterization of ISB 1342, a CD38 × CD3 T-cell engager for relapsed/refractory multiple myeloma
Blandine Pouleau, Carole Estoppey, Perrine Suere, et al.
Haematologica
|
February 13, 2008
Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders
Andy C Rawstron, Alberto Orfao, Meral Beksac, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 19, 2025
ESMO basic requirements for AI-based biomarkers in oncology (EBAI)
M Aldea, M Salto-Tellez, A Marra, et al.
Nature Cancer
|
September 11, 2024
ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells
Laura Carretero-Iglesia, Olivia J Hall, Jérémy Berret, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 19, 2026
ESMO Adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours
K S Saini, M Koopman, D Martins-Branco, et al.
Page
of 26
Search research articles
Search
Showing results (251-260 of 260) with videos related to
Sort By:
Page
of 26
You have reached the last page of results.
This site can display upto 260 results.
European Journal of Cancer (Oxford, England : 1990)
|
October 4, 2024
Olaparib as maintenance therapy in non resectable pancreatic adenocarcinoma associated with homologous recombination deficiency profile: A French retrospective multicentric AGEO real-world study
Jeannie M'Baloula, David Tougeron, Alice Boilève, et al.
Biology of the Cell
|
November 9, 2024
CRCI<sup>2</sup>NA inaugural symposium: A meeting on tumor and immune ecosystems
Vincent J Guen, Gwennan André-Grégoire, Céline Beauvillain, et al.
ESMO Real World Data and Digital Oncology
|
February 6, 2026
ESMO Guidance for Reporting Oncology real-World evidence (GROW)
L Castelo-Branco, A Pellat, D Martins-Branco, et al.
Cell Reports. Medicine
|
February 19, 2026
Targeting BCMA in multiple myeloma with a trifunctional NK cell engager
Alexandre Tang, Laurent Gauthier, Elisa Zaghi, et al.
Nature Communications
|
March 6, 2024
Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma
C Grandclément, C Estoppey, E Dheilly, et al.
Blood
|
May 16, 2023
Preclinical characterization of ISB 1342, a CD38 × CD3 T-cell engager for relapsed/refractory multiple myeloma
Blandine Pouleau, Carole Estoppey, Perrine Suere, et al.
Haematologica
|
February 13, 2008
Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders
Andy C Rawstron, Alberto Orfao, Meral Beksac, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 19, 2025
ESMO basic requirements for AI-based biomarkers in oncology (EBAI)
M Aldea, M Salto-Tellez, A Marra, et al.
Nature Cancer
|
September 11, 2024
ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells
Laura Carretero-Iglesia, Olivia J Hall, Jérémy Berret, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 19, 2026
ESMO Adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours
K S Saini, M Koopman, D Martins-Branco, et al.
Page
of 26